Why the study?
Determining whether malignant hyperthermia susceptibility can be principally genetically determined is of high importance to prevent its lethality through better understanding of pathogenesis.
This review provides updates on the genetics of malignant hyperthermia susceptibility to better understand the condition and current research.
Answers are grounded in this paper and cite their sources.
Genetic testing for MHS remains adjunctive to CHCT; leaves open whether it can become the principal diagnostic method.
Malignant hyperthermia susceptibility (MHS) and the associated condition malignant hyperthermia (MH) are rare but well-known disorders in the field of anesthesiology. MHS is usually determined by a history of a family member developing a positive episode during general anesthesia and then confirmed by an invasive caffeine halothane contracture test (CHCT). More recently, within the context of MH as a pharmacogenetic disorder, the question of whether or not MHS can be principally genetically determined is of high importance as knowledge of detailed pathogenesis may prevent against its largely invariable lethality if untreated. Thus, in this brief report, genetic terms, as well as updates in the genetics of MHS, will be reviewed in order to better understand both the condition and the current research.
No takes yet. Share an insight, caveat, or question.
Beebe et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: